Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 199 participants.

Also called NCT05966272

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 199 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05966272
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05966272. Randomized; triple masking; primary purpose treatment. Start 2023-08-12 (actual); primary completion 2024-09-24 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects
Intervention (Drug)
HRS9531 injection
Intervention (Drug)
HRS9531 injection Placebo
Lead sponsor
Fujian Shengdi Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05966272
Content hash
068fa1af287b0c7a6e7f8e254c1cdd5dbac328c0cc76d84bb2371d1a86e65991